Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 223Lymphoma, Large B-Cell, Diffuse 208Lymphoma, Non-Hodgkin 148Leukemia, Lymphocytic, Chronic, B-Cell 138Lymphoma, Follicular 130Lymphoma, Mantle-Cell 117Lymphoma, B-Cell, Marginal Zone 78Leukemia 72Burkitt Lymphoma 62Waldenstrom Macroglobulinemia 57Precursor Cell Lymphoblastic Leukemia-Lymphoma 46Lymphoma, B-Cell 45Recurrence 39Lymphoma, Large-Cell, Immunoblastic 33Hodgkin Disease 26Neoplasms 16Dendritic Cell Sarcoma, Interdigitating 16Lymphoma, Large-Cell, Anaplastic 14Leukemia, Myeloid, Acute 14Myelodysplastic Syndromes 12Leukemia, Hairy Cell 12Multiple Myeloma 11Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Hematologic Neoplasms 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Prolymphocytic 8Leukemia, Myeloid, Accelerated Phase 8Intraocular Lymphoma 8Neoplasms, Plasma Cell 7Leukemia, Myelomonocytic, Chronic 7

Interventions

dolutegravir 1acalabrutinib 1Tenofovir 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neuritis × Rituximab × Clear all
NCT05065554 2025-12-05

ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
12 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Neuritis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡